ADCLimited DatastaleDaiichi Sankyo Co., Ltd.Phase 2
Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))
Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic
#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 149Status Recruiting